Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 161 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mucositis Clear all
Terminated Not applicable Interventional

A Pilot Trial to Assess the Effects of Green Tea in the Prevention of Therapy-Induced Mucositis

NCT00176514
View directory record Official record
Conditions
Mucositis
Interventions
Administration of the antineoplastic
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

NCT03689712
View directory record Official record
Conditions
Oral Mucositis
Interventions
GC4419 90mg, Placebo
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
86
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Corona, California + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Beet Root in Locally Advanced Squamous Cell Cancer of the Head and Neck

NCT02058849
View directory record Official record
Conditions
Mucositis
Interventions
Beetroot, Placebo
Drug · Other
Lead sponsor
David Travis Thomas
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients

NCT01283906
View directory record Official record
Conditions
Oral Mucositis
Interventions
MuGard, Control Rinse
Device
Lead sponsor
Access Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
18
States / cities
Mesa, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients

NCT04752384
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Buprenorphine, Tramadol, Oral Mucositis (OM) Pain App
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

NCT02480114
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
Interventions
Educational Intervention, Gabapentin, Pain Therapy, Quality-of-Life Assessment, Questionnaire Administration, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen, Fentanyl, Ibuprofen, Magic Mouthwash
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

NCT02990468
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
BMX-001, Radiation Therapy, Cisplatin
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of RK0202 in Oral Mucositis

NCT00230191
View directory record Official record
Conditions
Mouth Diseases, Mouth Ulcers, Oral Mucositis, Head and Neck Cancer
Interventions
RK-0202
Drug
Lead sponsor
RxKinetix
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2007 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis

NCT02399228
View directory record Official record
Conditions
Oral Mucositis
Interventions
0.25% EISO mouth rinse
Drug
Lead sponsor
Santalis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 19, 2026, 6:42 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer

NCT02575313
View directory record Official record
Conditions
Mucositis
Interventions
Whole Food Intervention
Dietary Supplement
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

NCT01593124
View directory record Official record
Conditions
Vaginal Inflammation, Vaginal Infections
Interventions
Imiquimod, Placebo, Nonoxynol-9
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Not applicable Interventional

Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients

NCT02119897
View directory record Official record
Conditions
Oropharyngeal Mucositis, Myeloablative Hematopoietic Cell Transplantation, Low Level Light Therapy
Interventions
Low Level Light Therapy
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
4 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Not applicable Interventional Results available

Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis

NCT02608879
View directory record Official record
Conditions
Oral Mucositis, Oral Cancer
Interventions
Oral Mucosa Deterging and Periodontal Debridement (OMDP), Standard of Care Oral Hygiene Instructions, Dental scaling, ultrasonic, Chlorhexidine
Procedure · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

NCT00267046
View directory record Official record
Conditions
Sarcoma, Oral Mucositis
Interventions
Palifermin, Placebo, Adriamycin (Doxorubicin), Ifosfamide, Vincristine, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 19, 2026, 6:42 PM EDT
Terminated Phase 3 Interventional Results available

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

NCT00360971
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions
palifermin, cisplatin, placebo, neck dissection, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 19, 2026, 6:42 PM EDT
Completed No phase listed Observational

Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis

NCT01252498
View directory record Official record
Conditions
Cancer of the Head and Neck, Radiotherapy
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 19, 2026, 6:42 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Experimental Peri-implant Mucositis on Implant Sites That Were Previously Treated With or Without Implantoplasty

NCT06063876
View directory record Official record
Conditions
Peri-implant Mucositis, Peri-Implantitis
Interventions
Induction of experimental peri-implant mucositis, Resolution of experimental peri-implant mucositis
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

NCT01682031
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Xerostomia
Interventions
selenomethionine, placebo, cisplatin, radiation therapy, quality-of-life assessment
Dietary Supplement · Other · Drug + 2 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 4 Interventional

Subcutaneous Amifostine Safety Study

NCT00158041
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer, Lymphoma
Interventions
Amifostine administered subcutaneously
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

NCT00004132
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions
filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 19, 2026, 6:42 PM EDT
Terminated Phase 4 Interventional

Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients

NCT03490396
View directory record Official record
Conditions
Oral Mucositis
Interventions
Gelclair, First® Mouthwash BLM
Device · Combination Product
Lead sponsor
Midatech Pharma US Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 19, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Inflammation in Methamphetamine and STIs (IMSTI)

NCT05162391
View directory record Official record
Conditions
Methamphetamine-dependence, Rectal Gonorrhea, Rectal Chlamydia
Interventions
Contingency Management
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 19, 2026, 6:42 PM EDT
Not listed Phase 1Phase 2 Interventional

CelAgace™ OraRinse Solution for Treatment of Candidiasis

NCT03250923
View directory record Official record
Conditions
Candidiasis, Oral
Interventions
silver citrate complex and acemannan
Drug
Lead sponsor
CelaCare Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 19, 2026, 6:42 PM EDT
Recruiting Phase 3 Interventional

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

NCT06992427
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
212
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 171 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 6:42 PM EDT